TP53 and myelodysplastic syndrome: The mutant p53-targeting compound APR-246 (Eprenetapopt/PRIMA-1Met) is currently being tested in phase III clinical trials in myelodysplastic syndrome (MDS) and in several phase II trials in other hematological malignancies harboring TP53 mutations and has recently received Food and Drug Administration (FDA) Fast Track Designation for mutant TP53 acute myeloid leukemia (AML) and MDS.